摘要
PRDM 14属于含PR域(PRDM)家族。虽然人们对PRDM 14通过表观遗传机制来维持胚胎干细胞的干细胞和多能性的功能有着精确的认识,但越来越多的实验证据已经将PRDM 14与人类癌症联系起来。在成人中,PRDM 14在人体组织中的表达较低。PRDM 14的异常表达与多种恶性组织学类型和实体癌有关,其中PRDM 14可作为致癌过程的驱动因子。RPDM 14的过表达促进了癌细胞的生长,降低了肿瘤细胞对化疗药物的敏感性。降低PRDM 14在肿瘤细胞中的表达可增强药物对癌细胞的治疗敏感性,提示异常的PRDM 14在肿瘤治疗中可能具有致癌特性,是一种新的分子靶点。本文综述了PRDM 14在不同恶性肿瘤中的结构和致癌特性,认为PRDM 14可能是一种潜在的肿瘤治疗分子靶点。
关键词: PRDM 14,癌基因,化疗耐药,PRDM家族,分子治疗靶点,肿瘤治疗。
Current Cancer Drug Targets
Title:PRDM14: A Potential Target for Cancer Therapy
Volume: 18 Issue: 10
关键词: PRDM 14,癌基因,化疗耐药,PRDM家族,分子治疗靶点,肿瘤治疗。
摘要: PRDM14 belongs to the PR domain-containing (PRDM) family. Although a precise understanding focused on the function of PRDM14 to maintain stemness and pluripotency in embryonic stem cells via epigenetic mechanisms, growing experimental evidence has been linked PRDM14 to human cancers. In adults, PRDM14 has low expression in human tissues. Aberrant PRDM14 expression is connected with various malignant histological types and solid cancers, where PRDM14 can act as a driver of oncogenic processes. Overexpression of RPDM14 enhanced cancer cells growth and reduced cancer cells sensitive to chemotherapeutic agents. Reducing the expression of PRDM14 in cancer cells can enhance the therapeutic sensitivity of drugs to cancer cells, suggesting that aberrant PRDM14 may have a carcinogenic characteristic in tumor therapy and as a new molecular target. This review summarizes the structure and oncogenic properties of PRDM14 in different malignancies and suggests that PRDM14 may be a potential therapeutic molecular target for tumor treatment.
Export Options
About this article
Cite this article as:
PRDM14: A Potential Target for Cancer Therapy, Current Cancer Drug Targets 2018; 18 (10) . https://dx.doi.org/10.2174/1568009618666180430143055
DOI https://dx.doi.org/10.2174/1568009618666180430143055 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Innovative Cancer Drug Targets: A New Horizon in Oncology
Cancer remains one of the most challenging diseases, with its complexity and adaptability necessitating continuous research efforts into more effective and targeted therapeutic approaches. Recent years have witnessed significant progress in understanding the molecular and genetic basis of cancer, leading to the identification of novel drug targets. These include, but ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Combination Therapy with Arsenic Trioxide for Hematological Malignancies
Anti-Cancer Agents in Medicinal Chemistry Current Therapeutics, Their Problems and Thiol Metabolism as Potential Drug Targets in Leishmaniasis
Current Drug Metabolism Trabectedin as a New Chemotherapy Option in the Treatment of Relapsed Platinum Sensitive Ovarian Cancer
Current Pharmaceutical Design Cellular Senescence in the Development and Treatment of Cancer
Current Pharmaceutical Design Bronchomediastinal Fistula with Spontaneous Resolution in a Patient with Lung Cancer
Current Respiratory Medicine Reviews iPSCs Derived from Malignant Tumor Cells: Potential Application for Cancer Research
Current Stem Cell Research & Therapy Structure and Ligand-based Design of P-glycoprotein Inhibitors: A Historical Perspective
Current Pharmaceutical Design New Perspectives for Melanoma Immunotherapy: Role of IL-12
Current Molecular Medicine Epigenetic Modulation: A Promising Avenue to Advance Hematopoietic Stem Cell-Based Therapy for Severe Autoimmune Disorders
Epigenetic Diagnosis & Therapy (Discontinued) Biologically Active Synthetic Anionophores
Current Organic Chemistry The Anticancer Properties of Silibinin: Its Molecular Mechanism and Therapeutic Effect in Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Lactate in Solid Malignant Tumors: Potential Basis of a Metabolic Classification in Clinical Oncology
Current Medicinal Chemistry Current Strategies for Probing Substrate Specificity of Proteases
Current Medicinal Chemistry Target Therapies in Pancreatic Carcinoma
Current Medicinal Chemistry Editorial [Hot Topic: Tyrosine Kinase Inhibitors in Cancer Therapy (Guest Editor: S. Eckhardt)]
Anti-Cancer Agents in Medicinal Chemistry Proteomics on Fixed Tissue Specimens – A Review
Current Proteomics Breast Cancer: Biological Characteristics in Postmenopausal Type 2 Diabetic Women. Identification of Therapeutic Targets
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Therapeutic Nanoparticles and Associated Toxicity
Current Nanoscience Anti-Egfr Therapy in Colorectal Cancer: How to Choose The Right Patient
Current Drug Targets Radiolabeled Small Molecule Inhibitors of VEGFR - Recent Advances
Current Pharmaceutical Design